Pramlintide combination therapy

Drug Profile

Pramlintide combination therapy

Alternative Names: pramlintide + phentermine; pramlintide + PYY3-36; pramlintide + sibutramine; pramlintide/phentermine; pramlintide/PYY3-36; pramlintide/sibutramine

Latest Information Update: 05 Jan 2016

Price : $50

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Cyclobutanes; Macromolecular substances; Neuropeptides
  • Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Islet amyloid polypeptide stimulants; Leptin receptor agonists; Neuropeptide Y2 receptor agonists; Neurotransmitter stimulants; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 25 Dec 2012 Amylin Pharmaceuticals and Takeda terminate their agreement for this programme
  • 24 Feb 2010 Discontinued - Phase-II for Obesity in USA (Injection/PO combination)
  • 24 Feb 2010 Discontinued - Phase-II for Obesity in USA (Subcutaneous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top